To tackle the most critical unmet need in NASH, Cargene has exclusively in-licensed regenerative medicine-related technology from Singapore's Agency for Science, Technology and Research (A*STAR) to reduce liver fibrosis in NASH patients. Cargene is also developing technologies for targeted delivery of oligonucleotides to a variety of organs and tissues, and novel nucleosides to boost pharmaceutical efficacy of the siRNAs. Cargene was jointly founded by XQ Lin, Chairman and founder of EVX Ventures, Dr. Yann Chong Tan, a serial biotech entrepreneur who has co-founded a NASDAQ listed biotech company and Dr.Torsten Wuestefeld, principal investigator at A*STAR's Genome Institute of Singapore. Cargene has a scientific board of world-class scientists comprising Professors Harvey Lodish, Roger Foo, Kausik Ray, and Torsten Wuestefeld. Cargene has a founding team comprising biotech serial entrepreneurs and world-class experts in nucleic acid chemistry. Cargene is a preclinical-stage biopharmaceutical company developing oligonucleotide therapeutics for cardiovascular, fibrotic and pulmonary diseases.